Pharmaceutical enterprises from mainland China and Taiwan met Monday in Taipei in a first-ever forum that aims to forge tighter cross-Strait partnerships and cooperation in the biotechnology and medicine industry.
The Taiwan-based Institute for Biotechnology and Medicine Industry (IBMI) and the China Pharmaceutical Innovation and Research Development Association jointly organized the forum where pharmaceutical companies from both sides of the Strait can foster deeper cooperation in developing new drugs and capturing the global market.
Song Ruilin, executive chairman of China Pharmaceutical Innovation and Research Development Association, said that 11 drug companies from the mainland held nearly 40 face-to-face talks with 15 pharmaceutical businesses from the island during the forum.
Chen Weijao, chairman of the IBMI, explained why the forum will help businesses from both sides of the Strait. Taiwan, he said, has the technical expertise, experience and facilities for conducting clinical first-stage trials based on rigid regulation against established world-class pharmaceutical standards, while the Chinese mainland can provide patient samples, do second- and third-stage trials and, of course, has a huge potential drug market.
Drug companies from both sides of the Strait will achieve win-win outcomes in the Chinese pharmaceutical industry by entering the new partnership model.
Cross-Straits partnerships, whether formal or informal, whether for industrial, scientific, cultural or other purposes, have been long encouraged by the authorities and the ruling parties in both Taiwan and mainland China.
The two sides of the Strait are after all basically just one people who speak the same language. Recently, the cross-Strait affairs chiefs met in Beijing for a symposium.
China's Head of the State Council for Taiwan Affairs Office Zhang Zhijun and Taiwan's mainland affairs chief Wang Yu-chi agreed Wednesday to promote the peaceful development of cross-Strait relations.